Ionis touts PhIII success for rare disease drug amid company's push to commercialize drugs independently
Ionis Pharmaceuticals’ hereditary angioedema treatment helped cut the rate of attacks associated with the rare genetic disease in a Phase III study.
People with hereditary angioedema, or HAE for short, experience episodes of severe swelling in various parts of the body. In a pivotal study with 91 participants, those who received donidalorsen every four or eight weeks had a lower rate of attacks compared to those who received placebo, Ionis announced Monday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
